TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22284902

Group type: EXPERIMENTAL
Intervention: HM30181 180 mg single-dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 360 mg single-dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 600 mg single-dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 900 mg single-dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 60 mg multiple-dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 180 mg multiple-dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 360 mg multiple-dose
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 (all doses)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 (multiple doses)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HM30181 (360 mg repeated administration)
Number of subjects: 180
Study: 21084920

Group type: EXPERIMENTAL
Intervention: Unimanual massed practice (MP) training with somatosensory stimulation (SS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bimanual massed practice (MP) training with somatosensory stimulation (SS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both unimanual and bimanual MP + SS
Number of subjects: 13
Study: 18175733

Group type: EXPERIMENTAL
Intervention: High-protein diet (34% of energy)
Number of subjects: 79

Group type: COMPARATOR
Intervention: High-carbohydrate diet (64% of energy)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 79

Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 79
Study: 15920044

Group type: EXPERIMENTAL
Intervention: C therapy (combination therapy weight loss program for 2 years)
Number of subjects: 59

Group type: COMPARATOR
Intervention: S/C therapy (standard therapy weight loss program for 1 year followed by combination therapy in the 2nd year)
Number of subjects: 59
Study: 13679972

Group type: EXPERIMENTAL
Intervention: Immunotherapy with biologically standardized mushroom extract at a maintenance dosage of 0.1 mg/ml of Alt a I
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Immunotherapy with biologically standardized mushroom extract
Number of subjects: 28
Study: 10479145

Group type: EXPERIMENTAL
Intervention: Nonavalent pneumococcal conjugate vaccine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 8983438

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 23
Study: 1774653

Group type: EXPERIMENTAL
Intervention: Optical-zone-directed incisions
Number of subjects: 5

Group type: COMPARATOR
Intervention: Limbus-directed incisions
Number of subjects: 5
Study: 7075499

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31062540

Group type: EXPERIMENTAL
Intervention: Experimental group 1 (n=10) - 25-35 breaths at 55% maximal inspiratory pressure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental group 2 (n=10) - 45-55 breaths at 40% maximal inspiratory pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham-control group (n=10) - 30 breaths at 15% maximal inspiratory pressure
Number of subjects: 30
Study: 29074892

Group type: EXPERIMENTAL
Intervention: Levothyroxine for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication for 14 days (Control)
Number of subjects: 0
Study: 26588111

Group type: EXPERIMENTAL
Intervention: Extended-release naproxen sodium 660 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release naproxen sodium 220 mg tid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23949016

Group type: EXPERIMENTAL
Intervention: G-Bond (HEMA-free one-step adhesive)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Optibond FL (three-step etch-and-rinse adhesive)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both adhesives
Number of subjects: 52
Study: 21726428

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 46

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (Normal persons)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Latanoprost and Diclofenac
Number of subjects: 46
Study: 19386061

Group type: EXPERIMENTAL
Intervention: Cognition-oriented breast self-examination intervention program involving lectures, demonstrations, practice with models, and feedback.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 48
Study: 17662129

Group type: EXPERIMENTAL
Intervention: Pimecrolimus (Elidel cream 1%)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 16098458

Group type: EXPERIMENTAL
Intervention: 800 mg of imatinib daily
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Cross-over to high-dose imatinib after progression on 400 mg
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Cross-over to high-dose imatinib
Number of subjects: 946
Study: 12044735

Group type: EXPERIMENTAL
Intervention: Younger children (4-5 years)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Older children (7-8 years)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 293
Study: 10749030

Group type: EXPERIMENTAL
Intervention: Oat milk (0.75 liters/day for 5 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control drink (rice milk, 0.75 liters/day for 5 weeks)
Number of subjects: 66
Study: 8583020

Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery and scaling and root planning with Augmentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery and scaling and root planning with tetracycline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery and scaling and root planning with ibuprofen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery and scaling and root planning with placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Poor response group
Number of subjects: 40
Study: 2407812

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (tamoxifen 20 mg/d and low-dose prednisone 7.5 mg/d for one year)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Observation (no adjuvant therapy)
Number of subjects: 320
Study: 7355185

Group type: EXPERIMENTAL
Intervention: 10 compound CS‐US trials
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 compound CS‐US trials
Number of subjects: 36

Group type: COMPARATOR
Intervention: 30 compound CS presentations and 30 shock stimuli (Control group)
Number of subjects: 36
Study: 31504064

Group type: EXPERIMENTAL
Intervention: Mobile children (5-14 months)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Visible dirt on finger pads
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Dirty fingernails
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Dirty fingerpads and palms
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: All three types of observations (dirty fingernails, fingerpads, palms)
Number of subjects: 584
Study: 28982775

Group type: EXPERIMENTAL
Intervention: Virtual asthma clinic (VAC) with 8-monthly outpatient visits and monthly web-based monitoring
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Virtual asthma clinic (VAC)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care with 4-monthly outpatient visits
Number of subjects: 210
Study: 25611932

Group type: EXPERIMENTAL
Intervention: E-mail-delivered intervention focused on diet and physical activity
Number of subjects: 47

Group type: COMPARATOR
Intervention: General health information (Control)
Number of subjects: 47
Study: 23424242

Group type: EXPERIMENTAL
Intervention: IVPCA-cryo group
Number of subjects: 50

Group type: COMPARATOR
Intervention: IVPCA group
Number of subjects: 50
Study: 21555750

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 19556410

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate oral care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral care without antiseptic
Number of subjects: 56
Study: 17549773

Group type: EXPERIMENTAL
Intervention: Hands-on educational session (lecture and practice on mannequins)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual training (control group)
Number of subjects: 150
Study: 15081447

Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of brewed coffee)
Number of subjects: 77
Study: 11394242

Group type: EXPERIMENTAL
Intervention: Resistance exercise (ten exercises, three sets of ten repetitions maximum, 2 min rest between sets)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10
Study: 9517746

Group type: EXPERIMENTAL
Intervention: Abdominal drainage
Number of subjects: 319

Group type: COMPARATOR
Intervention: No abdominal drainage
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 319

Group type: COMPARATOR
Intervention: Nonsuction drainage
Number of subjects: 319
Study: 8288717

Group type: EXPERIMENTAL
Intervention: 100 mg E3 suppository
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 28
Study: 3056503

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 176

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 176
Study: 15840256

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily for 1 week
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg once daily for 1 week
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (stable coronary heart disease)
Number of subjects: 58
Study: 31894102

Group type: EXPERIMENTAL
Intervention: Helminth infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deworming (1 year after treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No helminth infections (urban Indonesians)
Number of subjects: 0
Study: 30857843

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both CB and RF ablation
Number of subjects: 58
Study: 28509934

Group type: EXPERIMENTAL
Intervention: High frequency, deep, repetitive transcranial magnetic stimulation (drTMS) of the medial prefrontal cortex for 16 weeks, 3 times a week during intensive phase and once a week during maintenance phase.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham condition of drTMS.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Self-report of FOG severity and cognitive scores.
Number of subjects: 9
Study: 26277774

Group type: EXPERIMENTAL
Intervention: Sertraline (75 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23443509

Group type: EXPERIMENTAL
Intervention: Telecare
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Secondary metrics
Number of subjects: 2600
Study: 21292253

Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy fertile men (Control)
Number of subjects: 72
Study: 19224846

Group type: EXPERIMENTAL
Intervention: Gemcitabine, methoxypolyethylene glycosylated liposomal doxorubicin, or topotecan
Number of subjects: 4312

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (reference arm)
Number of subjects: 4312
Study: 16823646

Group type: EXPERIMENTAL
Intervention: Outpatient procedure (OP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Overnight stay (OS)
Number of subjects: 50
Study: 12732605

Group type: EXPERIMENTAL
Intervention: MRA (spironolactone)
Number of subjects: 134
Study: 10924732

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1 g/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 9311486

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg.kg-1 in 250 mL of saline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 8286026

Group type: EXPERIMENTAL
Intervention: Epi-Lock dressing
Number of subjects: 38

Group type: COMPARATOR
Intervention: moist saline dressing
Number of subjects: 38
Study: 3724308

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.0 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2.0 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26655892

Group type: EXPERIMENTAL
Intervention: Videotape of a Black boy displaying ADHD-related behaviors
Number of subjects: 131

Group type: COMPARATOR
Intervention: Videotape of a White boy displaying ADHD-related behaviors
Number of subjects: 131
Study: 28242554

Group type: EXPERIMENTAL
Intervention: Elastic therapeutic tape
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-tape control
Number of subjects: 21
Study: 23563342

Group type: COMPARATOR
Intervention: Fluoroscopy-guided
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Navigation coupled with O-arm-guided
Number of subjects: 20
Study: 24007748

Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg/day on days 1-21) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22)
Number of subjects: 455

Group type: COMPARATOR
Intervention: High-dose dexamethasone (40 mg/day on days 1-4, 9-12, and 17-20)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 455

Group type: COMPARATOR
Intervention: High-dose dexamethasone
Number of subjects: 455
Study: 20215781

Group type: EXPERIMENTAL
Intervention: Vitamin E (Vi-E) treatment on the blood-side layer of a synthetic polysulfone dialyzer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polysulfone (PS) dialyzer without Vi-E treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Secondary analysis including baseline PTH and Vi-E levels
Number of subjects: 20
Study: 18416259

Group type: EXPERIMENTAL
Intervention: Array SA40N lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ReSTOR lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tecnis ZM001 lens
Number of subjects: 30
Study: 16609356

Group type: EXPERIMENTAL
Intervention: [99mTc]pertechnetate salivary gland scintigraphy (SGS) after intravenous injection of 370 MBq
Number of subjects: 93
Study: 12617384

Group type: EXPERIMENTAL
Intervention: Phonophoresis of naproxen (10%)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Iontophoresis of naproxen (10%)
Number of subjects: 61
Study: 10720082

Group type: EXPERIMENTAL
Intervention: Ro 45-2081 (50 mg, single intravenous injection)
Number of subjects: 7
Study: 8874590

Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin (20 micrograms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1571644

Group type: EXPERIMENTAL
Intervention: Office system intervention
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 98
Study: 3882614

Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 350
Study: 30033755

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS) training for 24 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group discontinued RAS training between weeks 8 and 16
Number of subjects: 60
Study: 28205476

Group type: EXPERIMENTAL
Intervention: CTS‐6 quantitative diagnostic tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CTS‐6 tool)
Number of subjects: 0
Study: 26503485

Group type: EXPERIMENTAL
Intervention: Computer-assisted clinical decision support system and performance-based incentives
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-intervention facilities
Number of subjects: 36
Study: 24448692

Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg/day
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 21781149

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 181

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 181
Study: 19071226

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg BID
Number of subjects: 270

Group type: COMPARATOR
Intervention: Salmeterol 50 microg BID
Number of subjects: 270
Study: 16835772

Group type: EXPERIMENTAL
Intervention: Buttress group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tension band group
Number of subjects: 14
Study: 15821394

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/RTV) (300/100 mg) once daily
Number of subjects: 358

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/RTV) (400/100 mg) twice daily
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Atazanavir/saquinavir (ATV/SQV) (400/1200 mg) once daily
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/RTV) and Atazanavir/saquinavir (ATV/SQV)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/RTV)
Number of subjects: 358
Study: 17313001

Group type: EXPERIMENTAL
Intervention: Needling method for regulating the spleen and stomach
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupoints around the eye (control group)
Number of subjects: 120
Study: 10224988

Group type: EXPERIMENTAL
Intervention: Education through monthly newsletters
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Education plus incentives for participation
Number of subjects: 1226

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 1226
Study: 8695740

Group type: EXPERIMENTAL
Intervention: Excision and primary suture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 120
Study: 2069516

Group type: EXPERIMENTAL
Intervention: Surfactant inhalation (1 ml; 10 mg per milliliter)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 11
Study: 6337003

Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 8
Study: 31601619

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Nexplanon
Number of subjects: 463
Study: 29579846

Group type: EXPERIMENTAL
Intervention: HTK + UW solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: HTK alone
Number of subjects: 40
Study: 26728882

Group type: EXPERIMENTAL
Intervention: Combination HIV-prevention intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Matched pairs recruitment process
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: RDS-2 method
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: RDS-diagnostic statistics
Number of subjects: 200
Study: 24501376

Group type: EXPERIMENTAL
Intervention: Low-level probes embedded within natural scenes with semantic manipulation via stimulus inversion or reversed playback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition with semantic interpretation intact
Number of subjects: 0
Study: 21848929

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) on bicycle ergometer 2 × 20 min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) of leg extensors (10 Hz for 60 min)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CON) without exercise
Number of subjects: 32
Study: 21143943

Group type: EXPERIMENTAL
Intervention: 24-week home-based program consisting of 150 minutes per week of tailored moderate physical activity
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 230
Study: 18173139

Group type: EXPERIMENTAL
Intervention: Erzhi Tiangui Granule (ETG) combined with Western medicine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 80
Study: 15309433

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO) 40 mL/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Refined olive oil (ROO) 40 mL/day
Number of subjects: 22
Study: 12126548

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH), 4.5 U Bid for 5‐7 days
Number of subjects: 60
Study: 10401999

Group type: EXPERIMENTAL
Intervention: Group 1 (0.25 I)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group 2 (1 I)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group 3 (1.5 I)
Number of subjects: 160
Study: 7586252

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 15 g infused over 24 hours
Number of subjects: 27
Study: 30809633

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control
Number of subjects: 196
Study: 31160243

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (200 mg/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (non-RES group)
Number of subjects: 204
Study: 28222178

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-Monounsaturated Fat (HMF) meal
Number of subjects: 24
Study: 25892271

Group type: EXPERIMENTAL
Intervention: Eptifibatide along with intensified antianginal therapy (group A)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Intensified antianginal therapy alone (group B)
Number of subjects: 461
Study: 22867975

Group type: EXPERIMENTAL
Intervention: Etanercept (12.5 mg) administered via intra-articular injections
Number of subjects: 27
Study: 21193172

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atomoxetine (ATM) 60 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Citalopram (CIT) 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLAC) (dextrose)
Number of subjects: 24